GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL, Inc. agreed to a private placement with Samsung C&T and Samsung Electronics Singapore for 1,570,308 common shares at $70.05 per share, pursuant to a Stock Purchase Agreement. Closing is conditioned on regulatory clearances, including CFIUS, and execution by January 31, 2026 of a business collaboration with Samsung C&T for exclusive Galleri commercialization in Korea and a strategic collaboration with Samsung Electronics.
The company plans to use net proceeds for general corporate purposes to support commercialization and reimbursement efforts. GRAIL will file a resale registration covering the shares within 180 days after closing.
GRAIL also disclosed preliminary Q3 2025 results: US screening revenue between $32.1–$33.1 million, total revenue between $35.7–$36.7 million, and losses from operations between $123.9–$126.9 million. Cash, cash equivalents, restricted cash and short-term marketable securities were approximately $547 million as of September 30, 2025. These figures are preliminary and unaudited.
GRAIL, Inc. (GRAL) reported an insider transaction on a Form 4. CEO and director Robert Ragusa executed an automatic sell-to-cover of 7,239 shares of common stock on 10/15/2025 at a weighted average price of $68.88 to cover withholding taxes upon award vesting and share delivery.
After the transaction, Ragusa beneficially owned 727,388 shares, held directly. The sale was reported under transaction code “S” and occurred as part of a block trade executed in multiple transactions.
GRAIL, Inc. (GRAL) reported a director equity grant on Form 4. On October 15, 2025, director Gregory Summe received 425 deferred stock units under the company’s deferred stock program and 2024 Equity Incentive Plan in lieu of $32,136.99 of cash director fees, based on the $75.52 closing price of the company’s common stock on the grant date. The awards vest immediately.
Following this transaction, Mr. Summe beneficially owned 38,794 shares, held directly.
GRAIL, Inc. (GRAL) reported a director equity grant. On 10/15/2025, Director Steven Mizell acquired 267 deferred stock units under the company’s deferred stock program and 2024 Equity Incentive Plan. The grant was issued in lieu of $20,164.38 of cash fees, using a price per share of $75.52 (the closing price on the grant date). The awards vest immediately upon grant. Following this transaction, the director beneficially owned 36,469 shares, held directly.
GRAIL, Inc. (GRAL) reported insider stock sales by President Joshua Ofman on a Form 4. On 10/15/2025, he sold 8,865 shares of common stock at an average price of $76.0276. On 10/16/2025, he sold 6,114 shares at an average price of $82.01.
Following these transactions, Ofman beneficially owns 381,818 shares directly. The filing notes the sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
Insider sale reported for GRAIL, Inc. (GRAL). The reporting person, Joshua J. Ofman (an officer listed as President), sold 81,385 shares of GRAIL common stock on 10/06/2025 in transactions executed as a block trade at a weighted average price of $62.5 per share. After the reported sale, Mr. Ofman beneficially owned 396,797 shares. The Form 4 was signed by an attorney-in-fact on 10/08/2025. The filer states the reported price is a broker-calculated weighted average for multiple sell-to-cover transactions and offers to provide detailed per-trade pricing on request.
CRCM and affiliated entities reported ownership of common stock of Grail, Inc. Combined filings show CRCM LP and related funds/vehicles collectively report beneficial ownership of 1,800,651 shares, representing 5% of the outstanding common stock based on a 36,047,799 share denominator. Individual CRCM vehicles report holdings ranging from 206,666 to 937,153 shares; the largest single reported holder among the group is CRCM G SPV, LP with 937,153 shares (2.6%). The filings state the shares are not held to change or influence control and include standard disclaimers of beneficial ownership by the investment manager and general partners. The reporting date for the required event is 10/06/2025.
Grail, Inc. (GRAL): Schedule 13G/A (Amendment No. 2) — CRCM LP and affiliated entities reported beneficial ownership of 1,842,651 shares of Grail common stock, representing 5.11% of the class. The group holds shared voting and dispositive power over 1,842,651 shares and no sole power. Percentages are based on 36,047,799 shares outstanding as of June 30, 2025.
Reporting persons include CRCM Opportunity Funds III & IV, CRCM Institutional Master Fund (BVI), CRCM G SPV, CRCM LP, CRCM LLC, their general partners, and Chun R. Ding. They certified the holdings were not acquired to change or influence control.
Joshua J. Ofman, President of GRAIL, Inc. (GRAL), reported a sale of 9,692 shares of common stock on 10/02/2025 at a reported price of $64.0025 per share. After the transaction he beneficially owns 478,182 shares. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025, and the Form 4 was signed by an attorney-in-fact on 10/03/2025. The report is a routine Section 16 disclosure showing an officer-initiated disposition under an established trading plan.
GRAIL, Inc. (GRAL) filed a Form 144 reporting a proposed sale of 89,237 shares of common stock with an aggregate market value of $5,848,592.98, based on an approximate sale date of 10/06/2025 on NASDAQ. The filing shows the securities were originally acquired on 10/03/2024 upon vesting of restricted stock units under the issuer's equity incentive plans; the acquisition amount reported is 152,810 shares and the stated nature of payment is services rendered with a payment date of 10/03/2025. The filing also discloses two recent sales by Joshua J. Ofman: 4,202 shares sold on 08/19/2025 for $134,548.04 and 9,692 shares sold on 10/02/2025 for $601,485.52. Certain filer identification fields (CIK/CCC and filer contact name) and issuer address details are not provided in the visible content.